title: Impact of pomalidomide therapy in multiple myeloma: a recent survey.
abstract: Pomalidomide (Pomalyst(®)) is a synthetic compound derived by modifying the chemical structure of thalidomide to improve its potency and reduce its side effects and third drug in the class of immunomodulatory drugs. Pomalidomide is under global development with Celgene Corporation, was approved by the U.S. Food and Drug Administration on February 8, 2013 to treat patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior therapies including bortezomib and lenalidomide. In October 2009, it has found orphan designation for the treatment of relapsed and refractory MM by the EMA, and on August 2013, marketing authorization has issued in Europe by gaining a positive response. It inhibits myeloma cell growth and angiogenesis directly. Pomalidomide is the latest myeloma cell growth inhibitor to be approved in both USA and EU. The predominant side effects are thrombocytopenia, neuropathy, and deep vein thrombosis. Pomalidomide is also being investigated in patients with amyloidosis, prostate cancer, small cell lung cancer, pancreatic cancer, graft-versus-host disease, and Waldenstrom's macroglobulinemia. This article reviews the available information on pomalidomide with respect to its clinical pharmacology, mechanism of action, pharmacokinetics, pharmacodynamics, metabolism, pre-clinical studies, and clinical trials.
authors.forename: Arvind
authors.initials: A
authors.lastname: Kumar
authors.forename: Mayur
authors.initials: M
authors.lastname: Porwal
authors.forename: Ankita
authors.initials: A
authors.lastname: Verma
authors.forename: Arun K
authors.initials: AK
authors.lastname: Mishra
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy*; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D007155:Immunologic Factors; D013792:Thalidomide; C467566:pomalidomide
keywords: Clinical trials,; Immunoglobulin,; Immunomodulatory,; Multiple myeloma,; Neutropenia; Pomalidomide,; Pomalyst®,; Thalidomide,